SYNE1-AS1: A Potential Drug Target and Biomarker (G100505475)

Target Name: SYNE1-AS1

NCBI ID: G100505475

SYNE1-AS1

Other Name(s): SYNE1 antisense RNA 1

SYNE1-AS1: A Potential Drug Target and Biomarker

Syne1 (synaptophysin-1) is a protein that is expressed in the central nervous system (CNS) and play an important role in the regulation of synaptic plasticity and neuronal communication. It is a member of the superfamily of transmembrane protein (SMP) family and is composed of four distinct isoforms: SYNE1, SYNE2, SYNE3, and SYNE4. The primary function of Syne1 is to regulate the intracellular trafficking of synaptic vesicles, which are involved in the release of neurotransmitters and modulating the electrical properties of neurons.

Several studies have identified potential drug targets based on Syne1, including those involved in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. These potential drug targets are derived from the knowledge that Syne1 is involved in the regulation of synaptic plasticity, which is the ability of the nervous system to adapt and change in response to experience. Therefore, drugs that can modulate synaptic plasticity may be effective in treating neurodegenerative diseases.

One potential drug target for Syne1 is the use of neurotransmitters such as dopamine and glutamate, which are involved in the regulation of neural circuits and are known to be affected by Syne1 dysfunction. The neurotransmitter release is regulated by the intracellular trafficking of synaptic vesicles, which are known to be influenced by Syne1. Therefore, drugs that can modulate the trafficking of synaptic vesicles may be effective in regulating neurotransmitter release and treat neurodegenerative diseases.

Another potential drug target for Syne1 is the modulation of the electrical properties of neurons, which is known to be influenced by Syne1. The electrical properties of neurons are regulated by the intracellular trafficking of ion channels, which are known to be influenced by Syne1. Therefore, drugs that can modulate ion channel function may be effective in treating neurodegenerative diseases.

In addition to its potential drug targets, Syne1 is also a potential biomarker for the diagnosis and monitoring of neurodegenerative diseases. The expression of Syne1 is known to be reduced in the brains of individuals with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Therefore, the reduction in Syne1 expression may be an indicator of the severity of the disease and can be used as a biomarker for the diagnosis and monitoring of neurodegenerative diseases.

In conclusion, Syne1 is a protein that is involved in the regulation of synaptic plasticity and neuronal communication. Its primary function is to regulate the intracellular trafficking of synaptic vesicles, which are involved in the release of neurotransmitters and the modulation of electrical properties of neurons. Several studies have identified potential drug targets based on Syne1, including those involved in neurodegenerative diseases. Additionally, Syne1 is also a potential biomarker for the diagnosis and monitoring of neurodegenerative diseases. Therefore, the development of drugs that can modulate Syne1 function may be an effective strategy in the treatment of neurodegenerative diseases.

Protein Name: SYNE1 Antisense RNA 1

The "SYNE1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SYNE1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets